|Bid||36.49 x 1300|
|Ask||37.19 x 200|
|Day's range||36.70 - 37.17|
|52-week range||30.90 - 37.37|
|PE ratio (TTM)||22.85|
|Earnings date||30 Jan 2018|
|Forward dividend & yield||1.36 (3.66%)|
|1y target est||38.57|
The Zacks Analyst Blog Highlights: Pfizer, Chevron, Cisco, Las Vegas Sands and Dominion Resources
Wall Street is already off to a hot start in the New Year, with the Dow surging to new heights and tech giants like Amazon (AMZN) and Nvidia (NVDA) picking up right where they left off. But as tempting as it might be to try to find the next hot tech stock, one of the best places to start searching for 2018's top picks might be where the massive institutional investors put their money.
Should Investors Be Interested in Vertex Pharmaceuticals in 2018? On October 25, 2017, Vertex Pharmaceuticals (VRTX) announced positive top-line results from its open-label Phase 3 trial that evaluated Orkambi in 60 children suffering with cystic fibrosis (or CF) who have two copies of the F508del mutation. The trial reached its primary endpoint of safety, and Orkambi demonstrated improvement in secondary endpoints such as nutritional status and sweat chloride.
Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? Teva Pharmaceutical Industries (TEVA) has been focused on maximizing its revenues through its market-leading generics portfolio. The company, however, has been facing stiff competition in the generics market from Mylan (MYL), Gilead Sciences (GILD), and Pfizer (PFE), which has resulted in price erosion in the generics market.
Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? Teva Pharmaceutical Industries (TEVA) has a debt of $34 billion on its balance sheet. The company is focused on reducing its net debt obligations to optimum levels over the coming years.
There's talk that tax reform could give biotech M&A a kick-start. If it does, then investors will want to keep tabs on these stocks.
Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? As part of its recent restructuring plan, Teva Pharmaceutical Industries (TEVA) announced a $3 billion restructuring plan in December 2017. As part of its cost-saving initiative, the company plans to shut down some of its manufacturing facilities and cut its employee base.
Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? In December 2017, Teva Pharmaceutical Industries (TEVA) announced a restructuring plan to recuperate sales. Its stock has had a bull run since the announcement, rising 44.5% since the company’s weak earnings results for fiscal 3Q17 on November 2, 2017.
Merck's (MRK) Keytruda rapidly grows as its key top-line driver. The Keytruda development program shows significant advancement in 2017.
Focus this week was on pipeline updates provided by several companies including Pfizer (PFE) at a healthcare conference while Novo Nordisk's bid to acquire Ablynx also made news.
Donald Trump says his corporate tax cuts are setting off a domino effect that will finally end the long, lean years for American wage-earners.
Parkinson's Disease emerges a lucrative area in want of curative therapies in the space. To this end, many players work toward launching new treatments in the market.
With the U.S.'s new tax law coming into effect, many companies will see a significant impact from changes in their effective tax rates (some more than others). In this note, we focus on some of the major pharmaceutical firms such as Pfizer, Johnson & Johnson, Merck and Bristol-Myers Squibb.
On December 14, 2017, Teva (TEVA) stock gained more than 10% on the back of the announcement of a comprehensive restructuring plan and additional measures to improve the company’s operational and financial performance. On December 14, 2017, the Generic Drugs ETF (GNRX) rose by approximately 1.0%. Teva Pharmaceuticals has a debt of $32 billion, which needs to be serviced in an organized manner to strengthen the company’s financials and bring down leverage.